Group

HOOK

Although Pompe disease is a rare inherited disorder, advances in diagnosis and treatment have significantly improved patient outcomes. Early recognition and timely intervention are essential to help preserve muscle function, support respiratory health, and improve quality of life.

HISTORY / OVERVIEW

Pompe disease is caused by mutations in the GAA gene, resulting in a deficiency of the enzyme acid alpha-glucosidase (GAA). Without enough of this enzyme, glycogen accumulates in lysosomes, particularly in skeletal, cardiac, and respiratory muscles, leading to progressive muscle weakness and other complications.

Pompe disease is broadly classified into:

• Infantile-onset Pompe disease (IOPD)

• Late-onset Pompe disease (LOPD)

TREATMENT APPROACHES

Enzyme Replacement Therapy (ERT)

Enzyme replacement therapy is the standard disease-specific treatment for Pompe disease. It involves regular intravenous infusions of recombinant acid alpha-glucosidase to help reduce glycogen accumulation.

ERT has been shown to improve survival and cardiac outcomes in many infants with IOPD and can help stabilize or slow disease progression in many individuals with LOPD, although responses vary.

Supportive Care

Comprehensive management may include:

• Respiratory support

• Physical therapy

• Occupational therapy

• Nutritional management

• Speech and swallowing therapy

• Cardiac monitoring (particularly in infantile-onset disease)

• Orthopedic care when needed

TREATMENT GOALS

• Slow disease progression

• Preserve muscle strength and mobility

• Maintain respiratory function

• Improve or stabilize cardiac function in affected infants

• Enhance quality of life

• Reduce disease-related complications

DIAGNOSIS AND MONITORING

Diagnosis may involve:

• Enzyme activity testing

• Genetic testing for GAA variants

• Blood tests (including muscle enzyme levels)

• Muscle imaging

• Pulmonary function testing

• Cardiac evaluation

• Functional assessments during follow-up

Early diagnosis—sometimes through newborn screening programs where available—can enable earlier treatment and improve outcomes.

CHALLENGES

Current treatment challenges include:

• Lifelong therapy requirements

• Variable treatment response among individuals

• Immune responses to enzyme replacement in some patients

• Progressive respiratory and skeletal muscle involvement despite treatment in some cases

• Access to specialized care and ongoing monitoring

EMERGING THERAPIES

Research is focused on:

• Next-generation enzyme replacement therapies

• Gene therapy

• Enzyme enhancement strategies

• Pharmacological chaperones

• Combination treatment approaches

• Improved drug delivery to skeletal muscle

These approaches are under investigation, and availability varies depending on regulatory approvals and clinical trial outcomes.

FUTURE OUTLOOK

Continued advances in molecular medicine, newborn screening, and precision therapies are expected to further improve the management of Pompe disease. Ongoing research aims to develop treatments that provide more durable enzyme activity, better muscle targeting, and potentially long-term disease control.

ENGAGEMENT QUESTION

Which area of innovation do you believe holds the greatest promise for improving Pompe disease care: earlier diagnosis through newborn screening, next-generation enzyme replacement therapies, gene therapy, or advances in multidisciplinary supportive care?